Article
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
Current oncology (Toronto, Ont.) - 17 Jun 2022
Tinker Anna V, Altman Alon D, Bernardini Marcus Q, Ghatage Prafull, Gien Lilian T, Provencher Diane, Salvador Shannon, Doucette Sarah, Oza Amit M
Abstract excerpt
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard of care maintenance therapy to prolong remission and prevent relapse following a response to first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.